These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
209 related articles for article (PubMed ID: 24911443)
1. Interaction of 5-HTT and HTR1A gene polymorphisms in treatment responses to mirtazapine in patients with major depressive disorder. Chang HS; Lee HY; Cha JH; Won ES; Ham BJ; Kim B; Lee MS J Clin Psychopharmacol; 2014 Aug; 34(4):446-54. PubMed ID: 24911443 [TBL] [Abstract][Full Text] [Related]
2. Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder. Kang RH; Wong ML; Choi MJ; Paik JW; Lee MS Prog Neuropsychopharmacol Biol Psychiatry; 2007 Aug; 31(6):1317-21. PubMed ID: 17618721 [TBL] [Abstract][Full Text] [Related]
3. Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. Kang RH; Chang HS; Wong ML; Choi MJ; Park JY; Lee HY; Jung IK; Joe SH; Kim L; Kim SH; Kim YK; Han CS; Ham BJ; Lee HJ; Ko YH; Lee MS; Lee MS J Psychopharmacol; 2010 Dec; 24(12):1755-63. PubMed ID: 19493959 [TBL] [Abstract][Full Text] [Related]
4. Relationship between G-protein beta-3 subunit C825T polymorphism and mirtazapine responses in Korean patients with major depression. Kang RH; Hahn SW; Choi MJ; Lee MS Neuropsychobiology; 2007; 56(1):1-5. PubMed ID: 17943025 [TBL] [Abstract][Full Text] [Related]
5. MAOA gene polymorphisms and response to mirtazapine in major depression. Tzeng DS; Chien CC; Lung FW; Yang CY Hum Psychopharmacol; 2009 Jun; 24(4):293-300. PubMed ID: 19382113 [TBL] [Abstract][Full Text] [Related]
6. Comments on "Association study of the serotonin transporter promoter polymorphism and mirtazapine antidepressant response in major depressive disorder". Pae CU Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):597-8. PubMed ID: 17919799 [No Abstract] [Full Text] [Related]
7. Association of ARRB1 polymorphisms with the risk of major depressive disorder and with treatment response to mirtazapine. Chang HS; Won ES; Lee HY; Ham BJ; Kim YG; Lee MS J Psychopharmacol; 2015 May; 29(5):615-22. PubMed ID: 25294870 [TBL] [Abstract][Full Text] [Related]
8. Serotonin transporter polymorphisms and side effects in antidepressant therapy--a pilot study. Popp J; Leucht S; Heres S; Steimer W Pharmacogenomics; 2006 Mar; 7(2):159-66. PubMed ID: 16515395 [TBL] [Abstract][Full Text] [Related]
9. Effect of serotonin receptor 2A gene polymorphism on mirtazapine response in major depression. Kang RH; Choi MJ; Paik JW; Hahn SW; Lee MS Int J Psychiatry Med; 2007; 37(3):315-29. PubMed ID: 18314859 [TBL] [Abstract][Full Text] [Related]
10. Low-dose mirtazapine in treatment of major depression developed following severe nausea and vomiting during pregnancy: two cases. Uguz F Gen Hosp Psychiatry; 2014; 36(1):125.e5-6. PubMed ID: 24034854 [TBL] [Abstract][Full Text] [Related]
11. Association of the adrenergic alpha 2a receptor--1291C/G polymorphism with weight change and treatment response to mirtazapine in patients with major depressive disorder. Lee HY; Kang RH; Paik JW; Jeong YJ; Chang HS; Han SW; Lee MS Brain Res; 2009 Mar; 1262():1-6. PubMed ID: 19401164 [TBL] [Abstract][Full Text] [Related]
12. Longitudinal analysis of the suicidal behaviour risk in short-term placebo-controlled studies of mirtazapine in major depressive disorder. Kasper S; Montgomery SA; Möller HJ; van Oers HJ; Jan Schutte A; Vrijland P; van der Meulen EA World J Biol Psychiatry; 2010 Feb; 11(1):36-44. PubMed ID: 20146649 [TBL] [Abstract][Full Text] [Related]
13. Meta-analysis of placebo-controlled trials with mirtazapine using the core items of the Hamilton Depression Scale as evidence of a pure antidepressive effect in the short-term treatment of major depression. Bech P Int J Neuropsychopharmacol; 2001 Dec; 4(4):337-45. PubMed ID: 11806859 [TBL] [Abstract][Full Text] [Related]
14. Interaction of serotonin-related genes affects short-term antidepressant response in major depressive disorder. Lin E; Chen PS; Chang HH; Gean PW; Tsai HC; Yang YK; Lu RB Prog Neuropsychopharmacol Biol Psychiatry; 2009 Oct; 33(7):1167-72. PubMed ID: 19560507 [TBL] [Abstract][Full Text] [Related]
15. The combined effects of the 5-HTTLPR and 5-HTR1A genes modulates the relationship between negative life events and major depressive disorder in a Chinese population. Zhang K; Xu Q; Xu Y; Yang H; Luo J; Sun Y; Sun N; Wang S; Shen Y J Affect Disord; 2009 Apr; 114(1-3):224-31. PubMed ID: 18848359 [TBL] [Abstract][Full Text] [Related]
16. The catechol-O-methyltransferase Val108/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Szegedi A; Rujescu D; Tadic A; Müller MJ; Kohnen R; Stassen HH; Dahmen N Pharmacogenomics J; 2005; 5(1):49-53. PubMed ID: 15520843 [TBL] [Abstract][Full Text] [Related]
17. Mirtazapine acutely inhibits salivary cortisol concentrations in depressed patients. Laakmann G; Hennig J; Baghai T; Schüle C Ann N Y Acad Sci; 2004 Dec; 1032():279-82. PubMed ID: 15677428 [TBL] [Abstract][Full Text] [Related]
18. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial. Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870 [TBL] [Abstract][Full Text] [Related]
19. Mirtazapine orally disintegrating tablet versus sertraline: a prospective onset of action study. Behnke K; Søgaard J; Martin S; Bäuml J; Ravindran AV; Agren H; Vester-Blokland ED J Clin Psychopharmacol; 2003 Aug; 23(4):358-64. PubMed ID: 12920411 [TBL] [Abstract][Full Text] [Related]